Sangui Bio’s discoveries are expanding
the utility of blood.

Red blood cells are the most abundant cell type in humans and the conventional view is that they are highly specialised cells that only function in the transport of gas. However, data from our research demonstrates that this perspective is now outdated. We have since developed technologies and methodologies that go beyond conventional venous blood analyses and enable large scale proteomics from a single microsample of blood.

Founded in 2015, Sangui Bio is a Sydney-based life sciences company aiming to revolutionise how blood is analysed and used in medicine by shifting the focus to red blood cells (RBCs) and microsampling. We are creating powerful investigatory tools for a range of inflammatory conditions with an initial focus on cancer. 

Cytokines are small, secreted signalling proteins, that act locally and systemically on a variety of cells. Cytokines regulate inflammation and the immune response. Due to their wide pro- and anti-inflammatory effects, cytokines have been implicated in most disease processes.
However, very low cytokine concentrations in plasma means that they are difficult to use as diagnostic tools.
 
Sangui Bio’s breakthrough discovery enables significantly more data to be obtained from a single blood sample and is already changing how clinical groups study biomarkers.